Why we should look at continuing CD38 antibodies after progression

from PharmOncology · host Ming-Hei Tai

There is an explosion of trials in the CD38 antibody space (daratumumab, isatuximab) in multiple myeloma. This episode goes over one key unanswered question which many of the trials are not attempting to answer.

Episode metadata supplied by the publisher feed · Published May 6, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Why we should look at continuing CD38 antibodies after progression

0:00 9:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of PharmOncology?

This episode is 9 minutes long.

When was this PharmOncology episode published?

This episode was published on May 6, 2026.

Can I download this PharmOncology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!